These mimetic drug candidates or more simple “mimetics” can, for example, be truncated, genetically improved, or more stable variants of the tumor suppressor protein itself (biological approach) or small molecules which mimic the function of the lost tumor suppressor protein. The gene discussed is TCHP; the disease is neoplasm.